Trump's New Tariff Bomb: 200% Duty on Generic Drugs, What It Means for India

Brief By Newsbrief / 12:15 PM on 23 Jul 2026

US President Donald Trump has unveiled a new tariff policy targeting imported generic medicines, proposing duties of up to 200% after a two-year zero-tariff window beginning on August 1. The announcement comes amid rising global economic uncertainty and is expected to have significant implications for international pharmaceutical trade, particularly for India, one of the world's largest suppliers of generic medicines.

According to Trump, all imported generic medicines will continue to enjoy 0% tariff for the next two years. After this transition period, a 100% tariff will be imposed for one year, followed by an increase to 200%. He said the measure is intended to encourage pharmaceutical companies to shift manufacturing operations to the United States. Companies that fail to establish production facilities within the given timeline could face higher import duties.

India is often referred to as the "Pharmacy of the World" due to its dominant position in generic drug manufacturing. According to the Global Trade Research Initiative (GTRI), India exported generic medicines worth $9.7 billion to the United States in 2025, accounting for 38% of the country's total pharmaceutical exports of $25.8 billion. Nearly one in every five generic medicines used in the US is manufactured in India.

Industry experts believe the immediate impact on Indian pharmaceutical companies will be limited because exports will continue under the zero-tariff regime for the next two years. This transition period provides Indian drug manufacturers with valuable time to reassess their business strategies, expand manufacturing facilities in the US, strengthen partnerships with American companies, and reduce potential risks from future tariffs.

While the short-term outlook remains stable, the proposed 100% and 200% tariffs could pose a major long-term challenge for India's pharmaceutical exports if implemented. The policy may also reshape global pharmaceutical supply chains as companies evaluate production and investment decisions in response to the changing US trade environment.